Novavax (NVAX) issued the following update on the U.S. FDA BLA for Novavax’s COVID-19 Vaccine: “Last week, Novavax responded to the formal communication received from the U.S. Food and Drug Administration for our Biologics License Application (BLA) and our response addresses the request for a postmarketing commitment for a clinical trial. PMCs by their nature are completed after BLA approval. PMCs are not unusual with many approved drugs and/or biologics having at least one PMC or requirement. We believe our application is approvable upon alignment on the details of the PMC. We look forward to continued engagement with the FDA.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- ‘Regulatory Headwinds Set to Bite,’ Says Top Analyst on Novavax Stock (NVAX)
- Novavax asked for new Covid-19 vaccine trial by FDA, WSJ reports
- Novavax asked by FDA to complete additional COVID trial, WSJ says
- Novavax down 10% after WSJ report on FDA request for additional vaccine trial
- Novavax has improved clarity on path forward for Nuvaxovid, says BofA